Autism therapy’s 40-hour standard faces scrutiny as evidence falls short

The 40-hour standard is no longer a safe shorthand

A booming autism-therapy industry has turned a treatment target into a business model, and that is where the accountability gap opens widest. Some young children are still pushed into schedules that can reach 40 hours a week, even though the evidence for simply adding more hours is far weaker than many families are led to believe. The pressure is real on every side: parents want help, states are trying to control Medicaid costs, and clinics have strong incentives to keep schedules full.

The scale of need has also risen sharply. In April 2025, the Centers for Disease Control and Prevention estimated that about 1 in 31 children age 8 in the United States had been identified with autism spectrum disorder, up from 1 in 36 in the prior estimate. That means more families are entering a system where intensity is often presented as the default, even when a child may need a narrower, more targeted plan.

Where the 40-hour benchmark came from

The idea that more therapy is automatically better has deep roots. A 1987 study helped shape the modern intensive-treatment norm, and it became part of the clinical culture around early autism intervention. Over time, the benchmark hardened into a kind of industry standard, with 40 hours a week treated not as one option among many, but as the benchmark that families are supposed to chase.

That history matters because the original evidence base was narrow and has since been stretched far beyond its origins. What began as one influential study became a broad expectation across clinics, insurers and parent-facing advice. Once a number becomes the norm, it can be difficult to question, even when later research fails to show that the same dose works for all children.

What the newer evidence actually shows

A JAMA Pediatrics meta-analysis published June 24, 2024 examined 144 studies covering 9,038 children. Its central finding was blunt: none of the models showed a significant association between intervention amount and intervention effects. In plain terms, the review did not find robust evidence that outcomes improve simply because early childhood intervention is intensified.

That does not mean autism therapy is ineffective. It means the evidence does not support a blanket assumption that more hours reliably produce better results. For some children, focused behavioral support, parent coaching, speech therapy, occupational therapy or other targeted services may be more appropriate than a maximal weekly schedule. The key distinction is between evidence-based intensity for a specific child and an institutional habit of overprescribing hours because the market has room to fill them.

How money changes the shape of care

The concern is not just clinical. Outside analysis and reporting have linked the industry’s rapid growth to Medicaid spending pressure, private equity investment and growing scrutiny over billing, supervision and quality of care. Those forces can push clinics toward longer schedules and more billable services, even when the benefit to a child is uncertain.

The financial stakes are easy to see in state audits. In North Carolina, auditors reported autism therapy Medicaid billings jumping from $6 million in 2021 to $660 million in 2025. That kind of growth is not just a line item problem; it signals how quickly a service category can expand when reimbursement is generous and oversight lags behind demand.

Wisconsin offers another warning sign. The U.S. Department of Health and Human Services Office of Inspector General found that Wisconsin Medicaid made at least $18.5 million in improper fee-for-service ABA payments. Improper payments do not automatically prove fraud in every case, but they do show how vulnerable the system is when billing structures are complex and supervision is uneven.

Private equity has changed the market structure

Autism care is also part of a wider consolidation story in health care. Brown University reported that private equity firms acquired more than 500 autism centers over the past decade, and a 2026 study summary identified 574 private-equity-owned autism therapy centers across 42 states as of 2024. That footprint matters because ownership structure can shape staffing, billing intensity and pressure to grow revenue.

Private equity does not automatically mean lower quality, but the incentives are different from those of a small practice built around long-term family relationships. Investors typically expect expansion, margin improvement and predictable returns. In a field where therapy hours are billable and supervision can be costly, that can tilt decision-making toward volume.

How to tell evidence-based care from overprescribing

Not every intensive program is excessive, and some children do benefit from substantial support. The problem is the blanket assumption that 40 hours is a universal target, rather than one possibility that should be justified child by child. Families should expect a plan that ties hours to specific goals, regular progress checks and clear reasons for any increase.

A more evidence-based approach usually has a few traits:

• It starts with the child’s needs, not a preset weekly quota.
• It sets measurable goals for communication, daily living skills and behavior.
• It explains why each service is included and how progress will be reviewed.
• It adjusts intensity when the child is improving, plateauing or becoming overwhelmed.
• It does not treat more hours as the same thing as better care.

By contrast, overprescribing often shows up as a high-hour plan that is hard to explain, hard to change and difficult to separate from billing incentives. If a clinic cannot clearly connect the recommended volume to a child’s functioning, that should be treated as a warning sign.

The larger policy test

The autism-therapy debate is no longer just about one treatment model. It is about whether public programs can pay for care without rewarding excess, and whether regulators can spot weak supervision before costs explode. The numbers from North Carolina, Wisconsin and the private-equity rollup show how quickly an evidence-based service can become a financial machine.

Some providers still argue that intensive ABA remains beneficial for certain children, and that is an important part of the picture. But the broader evidence now makes one thing clear: intensity should be a clinical decision, not an industry reflex. The next phase of autism care will be defined by whether states, insurers and families demand proof that more hours are truly helping, not just filling schedules.